Janney Montgomery Scott LLC Has $58.14 Million Stock Position in Pfizer Inc. $PFE

Janney Montgomery Scott LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 3.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,414,370 shares of the biopharmaceutical company’s stock after acquiring an additional 80,019 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Pfizer were worth $58,138,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new stake in Pfizer during the 4th quarter worth about $1,830,986,000. Morgan Stanley boosted its stake in shares of Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after buying an additional 13,581,757 shares during the period. Janus Henderson Group PLC grew its position in shares of Pfizer by 577.5% during the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after buying an additional 7,489,189 shares during the period. Finally, Capital World Investors raised its stake in shares of Pfizer by 51.5% during the fourth quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock worth $533,704,000 after buying an additional 7,287,194 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on PFE shares. Wolfe Research restated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Guggenheim dropped their target price on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Citigroup increased their price target on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. BMO Capital Markets reduced their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Finally, Weiss Ratings cut Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $28.28.

Pfizer Stock Up 3.7%

Shares of NYSE:PFE opened at $28.25 on Thursday. The company has a 50 day moving average price of $25.23 and a two-hundred day moving average price of $26.23. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market capitalization of $161.00 billion, a PE ratio of 37.17 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the firm posted $0.78 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.1%. Pfizer’s payout ratio is currently 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 melanoma results for their personalized mRNA cancer-vaccine combination with Keytruda, demonstrating improved recurrence-free survival. Pfizer is not directly involved, but the data lifted sentiment across mRNA and oncology companies and highlighted the potential value of Pfizer’s own cancer-vaccine ambitions. Pfizer Stock Rises Wednesday: What’s Going On?
• Positive Sentiment: Pfizer and Valneva received validation from the European Medicines Agency for their Lyme disease vaccine application, allowing the filing to proceed to full regulatory review after encouraging late-stage efficacy and safety results. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Positive Sentiment: Unusually heavy call-option activity indicated increased speculative interest: investors bought 170,284 call options, roughly 47% above typical daily volume. This is a sentiment signal rather than a change to Pfizer’s fundamentals.
• Positive Sentiment: Pfizer’s potential monthly obesity treatment, berobenatide, could provide entry into the fast-growing GLP-1 market if clinical development and market-share objectives are achieved. Pfizer’s Obesity Push
• Neutral Sentiment: Merck’s increased investment in personalized cancer vaccines raises the competitive bar for Pfizer and BioNTech. The development validates the market opportunity but could make it harder for Pfizer to differentiate its pipeline. Merck Just Raised the Stakes for Pfizer’s Cancer Vaccine Ambitions
• Negative Sentiment: Investors continue to debate Pfizer’s looming patent cliff, which could pressure revenue as key products face loss-of-exclusivity risk. The stock’s relatively low valuation and dividend appeal may partly reflect these concerns. Pfizer: Still Cheap Valuation Meets a Looming Patent Cliff

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.